Newsroom — Singlera Genomics

On May 6, 2023, Breakthrough Genomics, a company based in the United States, launched early cancer screening and testing services in California. The launch ceremony was attended by Fiona Ma, the Treasurer of California, Dr. Laura Li, founder and CEO of Breakthrough Genomics, as well as leaders and guests, including Mr. Liu Qiang, co-founder and COO of Singlera Genomics. Phoenix TV reported on the event. Singlera Genomics, as the technical support provider for Breakthrough Genomics, will use its pancreatic cancer liquid biopsy technology PDACatchTM to assist in serving a wide range of patients. PDACatchTM testing received breakthrough medical device certification from the U.S. Food and Drug Administration (FDA) in April of this year. PDACatchTM is a novel liquid biopsy detection technology based on DNA methylation, used for detecting pancreatic cancer in high-risk populations.

Breakthrough Genomics is now preparing to conduct large-scale clinical trials, offering PDACatchTM testing services to high-risk populations, including individuals with newly diagnosed diabetes, chronic pancreatitis, and other genetic risk factors. The company plans to provide this service through its CAP and CLIA-certified genomics laboratory in Irvine and offer it as a Laboratory Developed Test (LDT) to healthcare providers and their patients.

Minister Fiona Ma stated, "I am delighted to be here; our Southern California companies and scientific leaders are using world-class innovative technology to save lives." Dr. Laura Li, founder and CEO of Breakthrough Genomics, expressed, "So many people and their loved ones are affected by cancer, so we are honored to be part of this effort, continually improving this life-saving technology and providing this crucial testing service to those in need."

Singlera Genomics and Breakthrough Genomics had previously signed a strategic cooperation agreement in 2022 to jointly explore the U.S. cancer early screening market. In the future, Breakthrough Genomics will launch a series of products and services developed by Singlera Genomics to serve a wide range of patients in the United States. Mr. Liu Qiang, co-founder and COO of Singlera Genomics, stated, "As an important step in the company's internationalization strategy, Singlera Genomics will leverage its technological advantages, collaborate with partners, and bring more and better products and services to the world."

Singlera Genomics, in collaboration with Clinomics. Launching early cancer detection services.

🕒 April 28, 2023

Singlera Genomics announced a strategic cooperation agreement with Clinomics USA, a subsidiary of South Korean company Clinomics. Mr. Liu Qiang, co-founder and Chief Operating Officer of Singlera Genomics, attended the signing ceremony. This marks one of Singlera Genomics' significant steps in expanding its overseas market, demonstrating international recognition and favor for Singlera Genomics' technological capabilities in the global market.

After the signing of the agreement, the collaborating parties plan to establish a global strategic partnership for early cancer detection and diagnosis based on liquid biopsy. They intend to conduct business in early cancer detection and diagnosis based on blood globally. Both parties have reached an agreement to launch Singlera Genomics's independently developed ColonES® (colorectal cancer), PDACatch™ (pancreatic cancer), and PanSeer® (pan-cancer screening technology) testing services to the market. These services will be offered through Clinomics Irvine CLIA Lab located in the United States.

Mr. Liu Qiang expressed that the collaboration with Clinomics is a crucial step for Singlera Genomics in expanding its global market presence. Early cancer screening can effectively reduce the risk of illness, as well as the associated pain and economic burden, impacting the well-being of people worldwide. Singlera Genomics possesses advanced technology in the field of cancer early screening, and partnering with Clinomics will facilitate the efficient promotion and application of these technologies in relevant areas. This collaboration holds significant positive implications for Singlera Genomics, the early cancer screening industry, and people worldwide. In the future, Singlera Genomics will continue to deepen its involvement in this field, making every effort to keep people away from the suffering caused by cancer.

Clinomics (352770.KQ) is a South Korean biomedical innovation company dedicated to advancing the development and commercialization of liquid biopsy and multi-omics-based early cancer diagnostic technologies. In the first half of this year, they began introducing related early tumor detection products and expanded their presence to the United States, Europe, Japan, South Korea, and other Asian markets. According to the U.S. global market analysis firm GLOBE NEWSWIRE, as of 2022, the global early cancer diagnosis market is valued at $171.6 billion (approximately ¥1.213 trillion), with an annual growth rate of 8.6%. In order to provide services to the global market, Clinomics established subsidiaries in the United States and Hungary six years ago, setting up laboratories, human resource centers, and other infrastructure for clinical services related to early cancer diagnosis. They have also obtained relevant national/regional certifications for such services.